Please fill out the pre-assessment below before the session begins.

Please enable JavaScript in your browser to complete this form.

1.   Which of the following has been shown to improve survival in patients with newly diagnosed FLT3-ITD mutated AML? *

2.  Which of the following statements regarding the use of menin inhibitors in AML is correct?

A. Addition of menin inhibitors to frontline induction regimens has clearly demonstrated higher response in patients with NPM1 mutated or KMT2A rearranged AML
B. Menin inhibitors have proven efficacy in the treatment of patients with relapsed NPM1 mutated or KMT2A rearranged AML
C. Menin inhibitor therapy has not been associated with differentiation syndrome
D. Menin inhibitors cannot be combined with other agents due to their significant toxicity profile

3.  Which of the following statements regarding low intensity therapy in patients with AML is true?

A. Lower intensity therapy with hypomethylating agents and venetoclax should be offered to all newly diagnosed patients with AML.
B. Addition of a third agent such as IDH inhibitors or FLT3 inhibitors to the combination of HMA and venetoclax has been associated with lower response rates and should be avoided.
C. MRD monitoring is not appropriate in the setting of lower intensity therapy as the responses are not deep enough.
D. The response and long-term survival associated with HMA plus venetoclax are highly dependent on AML biology and molecular profile.

Medical Learning Institute Inc
40946 US Highway 19N #602
Tarpon Springs, FL 34689
888.654.2631 (toll-free)
609.333.1693 (direct)

Scroll to Top

Please fill out the pre-assessment below before the session begins.​